EUVIMEDEUVIMED entdecken
Crossref

The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study

Li Hu, Zhoutian Yang, Zhenyun Yang, Wei Peng, Xiang Tang, Zhiwei Ye, Juncheng Wang, Yizhen Fu, Dandan Hu, Minshan Chen, Yaojun Zhang, Jinbin Chen

Hepatology International · 2025

DOI: 10.1007/s12072-024-10757-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology International, 2025. Verfasst von Li Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Phenylurea Compounds, Carcinoma, Hepatocellular, Liver Neoplasms, Pyridines. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Regorafenib is the recommended second-line therapy for unresectable hepatocellular carcinoma (uHCC). Our study aimed to assess the effect of transition timing to second-line therapy with regorafenib on treatment outcomes in uHCC patients. METHODS: In this retrospective study, patients were categorized into prompt transition group (PT group) or delayed transition group (DT group) based on the transition timing to second-line therapy with regorafenib following the first or subsequent occurrence of progressive disease during first-line treatment. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. RESULTS: There were 85 and 122 patients in the PT and DT groups, respectively. The PT group demonstrated significantly better median PFS [4.5 months (95% CI 3.8-6.0) vs. 3.4 months (95% CI 2.8-4.1); HR 0.641; 95% CI 0.478-0.859; p = 0.003], ORR (24.7% vs. 9.8%, p = 0.007), DCR (69.4% vs. 54.9%, p = 0.049), and median OS [17.5 months (95% CI 13.4-not reached) vs. 10.4 months (95% CI 7.9-15.6); HR 0.613; 92% CI 0.432-0.871, p = 0.006] compared to the DT group. Moreover, the overall safety profiles were comparable between groups. CONCLUSION: The prompt transition to second-line therapy with regorafenib following first-line treatment progression suggests better treatment outcomes and potentially longer survival than in patients who delay the transition to second-line therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsCarcinoma, HepatocellularLiver NeoplasmsPyridinesAntineoplastic AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment OutcomeProgression-Free SurvivalAdultTime Factors

Stichwörter der Autor:innen

Hepatocellular carcinomaRegorafenibSecond-line therapyTherapeutic strategy

Substanzen

regorafenibPhenylurea CompoundsPyridinesAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
  • Department of Liver Surgery, Sun Yat-Sen University Cancer Center, No. 651, Dongfeng East Road, Guangzhou, 510060, Guangdong, People's Republic of China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. zhangyuj@sysucc.org.cn.
  • Department of Liver Surgery, Sun Yat-Sen University Cancer Center, No. 651, Dongfeng East Road, Guangzhou, 510060, Guangdong, People's Republic of China. zhangyuj@sysucc.org.cn.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. chenjb@sysucc.org.cn.
  • Department of Liver Surgery, Sun Yat-Sen University Cancer Center, No. 651, Dongfeng East Road, Guangzhou, 510060, Guangdong, People's Republic of China. chenjb@sysucc.org.cn.

Zitieren

APA

Hu, L., Yang, Z., Yang, Z., Peng, W., Tang, X., Ye, Z., Wang, J., Fu, Y., Hu, D., Chen, M., Zhang, Y., & Chen, J. (2025). The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study. Hepatology International. https://doi.org/10.1007/s12072-024-10757-4

Vancouver

Hu L, Yang Z, Yang Z, Peng W, Tang X, Ye Z, et al. The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study. Hepatology International. 2025. doi:10.1007/s12072-024-10757-4

BibTeX
@article{Hu2025,
  author = {Hu, Li and Yang, Zhoutian and Yang, Zhenyun and Peng, Wei and Tang, Xiang and Ye, Zhiwei and Wang, Juncheng and Fu, Yizhen and Hu, Dandan and Chen, Minshan and Zhang, Yaojun and Chen, Jinbin},
  title = {The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study},
  journal = {Hepatology International},
  year = {2025},
  doi = {10.1007/s12072-024-10757-4}
}
Kostenlos starten →